| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物董事长 | | 3 | 严建亚 | 巨子生物董事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷青事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物青事长 | | 8 | 前烙 | 美年健康青事长 | | 9 | 傅海曙 | 瑞丽医美毒事长 | | 10 | (1) 郭振宇 | 贝泰妮董事长 | | | 接单尚明:排名不分先后,围绕专业能力、业绩表现 行业/ | | | | 响力等维度综合评选得出。 | | "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 严建亚，1966年9月出生，于1988年7月于中国西北大学获得化学工程学士学位。自2021年11月30日起获 委任为公司的董事，现为公司的执行董事、董事会主席、首席执行官、提名委员会及公司管治委员会之 主席，以及薪酬委员会之委员。他于2000年5月创立集团；于2002年，创立西安威力通 ...

Core Viewpoint - The OTC channel presents significant opportunities for beauty brands, offering professional endorsements, precise targeting of skincare needs, and immediate product experiences, but it also poses challenges due to strict professional requirements and a talent shortage in the industry [1][2][3]. Group 1: Market Entry and Growth - By 2025, over six domestic cosmetic companies are expected to enter the OTC channel, marking it as the "Year of Domestic Beauty OTC Layout" [2]. - Leading domestic beauty brand Proya (603605.SH) announced its entry into the OTC channel in January 2026, joining a growing list of companies [2]. - Brands like Winona and Kefu Beauty have been early entrants into the OTC channel, with Winona's sales nearing 1 billion yuan in 2023, capturing over 60% of the market share in this channel [5]. Group 2: Strategic Developments - In April 2025, Furuida Bio announced plans to accelerate its OTC channel development, aiming to cover 10,000 drugstore chains and launch 100 "cosmetic and medicinal" SKUs [5]. - Companies are increasingly focusing on integrating with the professional environment of pharmacies rather than merely distributing products [5]. - Proya is preparing multiple products for the OTC channel, emphasizing the importance of medical device products as a foundation for entry [6]. Group 3: Market Potential and Challenges - The OTC channel has approximately double the growth potential, with Winona targeting to cover 250,000 pharmacies [8]. - As of December 2024, there are about 705,000 licensed drug retail enterprises in China, with Winona covering over 110,000, representing about one-seventh of the total retail pharmacy stores [9]. - The demand for beauty products in pharmacies is rising due to pressures on traditional pharmacy profits and the need for transformation [9]. Group 4: Profitability and Talent Shortage - Medical device products have a significantly higher gross margin, averaging 77%-83%, compared to regular cosmetic products [9]. - The beauty industry faces a talent shortage in the pharmacy channel, as many brands rely on pharmacists who must understand both pharmaceuticals and cosmetics [10]. - Companies like Betaini are addressing this by training pharmacy staff to enhance customer trust and provide professional consultations [10][11].

《公司的秘密7》年度研报合集 "穿越热点，看到秘密" 预售已开启 2026年1月25日之后开始发货 01 所有人都在追的热点公司， 在《第一财经》杂志内部，研报长期被视为一种"静态报道"。 所谓静态，不追逐当下热度，不围观股价起伏；看长线、看基本面，看那些暂时不喧哗但真正重要的变 量。 而它们往往不会是社交媒体上最热闹的那一批，过去6册《公司的秘密》几乎都遵循了这一逻辑。 在即将发布的第7册里，这个规律被打破了。 我们把它拆解给你看 回看 2025 年我们发表的 12 篇研报，你会发现一个明显变化——它们几乎全部围绕年度商业热点展开。 △ 点击即可预订《公司的秘密7》 当然，这些公司之所以能被《第一财经》杂志选中成为研报对象，并不是因为声量，而是因为足够重要 和有趣。 和以往一样，编辑和记者做的，并不是复述新闻、放大情绪，而是持续做一件"有点反直觉"的事：从财 报、采访和公开数据里，挖掘那些被常规商业报道有意或无意忽略的信息。 你会看到—— 寒武纪，在夏天一度超越茅台，成为中国 A 股市值第二 泡泡玛特出海业绩增长超 400%，Labubu 成为全球级网红 霸王茶姬、地平线、Figma，完成各自行业里具有标志 ...

机构：西部证券 研究员：吴岑/于佳琦 事件：2026 年1 月15 日公司收到中国国家药品监督局颁发的关于"重组I型α1 亚型胶原蛋白及透明质酸 钠复合溶液"产品的第Ⅲ类医疗器械注册证。 此次最新获批的第二款产品"重组Ⅰ型α1 亚型胶原蛋白及透明质酸钠复合溶液"，是一款直接可注射的 预配溶液，其成分创新性地将等浓度的重组胶原蛋白（4.5mg/mL）与透明质酸钠（4.5mg/mL）结合， 旨在通过真皮层注射改善面颊部平滑度，精准定位于大众化的肤质改善与水光焕肤需求。通过"固体冻 干纤维填充"与"液体复合溶液焕肤"的组合，公司以同一技术基底实现了对注射医美中"去皱"与"肤质改 善"两大主流需求的差异化覆盖。 作为重组胶原蛋白领域平台型龙头，公司"技术-品牌-渠道"的全产业链布局形成了强有力的核心竞争 力：上游自主研发的重组胶原蛋白与合成生物技术平台，为产品筑牢技术与量产根基，两款Ⅲ类医疗器 械的获批更验证了平台的合规性与先进性，为后续产品拓展铺路；中游凭借"可复美+可丽金"双品牌矩 阵及医用敷料积累的医院渠道信任，为医美产品渗透赋能，而Ⅲ类械落地推动品牌从护肤级升级至医疗 级；下游依托线上线下全域渠道网络，助力医 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Insights - The company has received approval for the world's first injectable recombinant collagen and hyaluronic acid composite solution, marking a significant milestone in its product offerings [8] - The company is expected to see a compound annual growth rate (CAGR) in revenue of 49.0% in 2023, followed by 57.2% in 2024, and a more moderate growth of 15.8% and 14.7% in 2026 and 2027 respectively [6][8] - The company has a strong pipeline in the aesthetic medicine sector, with two approved recombinant collagen products, which are anticipated to drive substantial revenue growth [8] Financial Summary - Closing price is HKD 35.40, with a market capitalization of HKD 37.91 billion [6][7] - Projected revenue for 2023 is RMB 3,524.14 million, increasing to RMB 7,428.23 million by 2027 [6] - Projected net profit for 2025-2027 is RMB 19.3 billion, RMB 22.6 billion, and RMB 25.4 billion respectively, with a notable decline of 6.3% in 2025 followed by growth in subsequent years [8] - The company maintains a low debt-to-asset ratio of 18.58% [7]

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company has received approval from the National Medical Products Administration of China for its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution," marking a significant milestone in its product development [1][2]. - The company has successfully launched two key Class III medical devices, enhancing its competitive edge in the recombinant collagen sector [3]. - The dual product strategy addresses both wrinkle reduction and skin quality improvement, catering to diverse consumer needs in the aesthetic medicine market [2][3]. Financial Projections - Revenue is projected to grow from 3,524 million in 2023 to 7,204 million in 2027, with a peak growth rate of 57.2% in 2024 [4]. - Net profit is expected to increase from 1,452 million in 2023 to 2,630 million in 2027, with a notable growth rate of 44.9% in 2023 [4]. - Earnings per share (EPS) are forecasted to rise from 1.49 in 2023 to 2.46 in 2027, reflecting a strong upward trend in profitability [4]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 21.1 in 2023 to 12.8 in 2027, indicating an improving valuation as earnings grow [4]. - The price-to-book (P/B) ratio is expected to decline from 7.2 in 2023 to 2.7 in 2027, suggesting a more favorable valuation relative to book value over time [4].

Group 1 - The article reports on stock buybacks conducted by various companies on January 16, 2026, with Xiaomi Group-W (01810) having the largest buyback amount of 219 million yuan for 5.90 million shares [1][2] - Other notable buybacks include Sunyu Optical Technology (02382) with 1.13 million shares repurchased for approximately 74.9 million yuan and Xiansheng Pharmaceutical (02096) with 4.43 million shares for about 51.6 million yuan [1][2] - The total number of shares repurchased by Xiaomi Group-W represents 0.71% of its total share capital, while Sunyu Optical Technology's buyback accounts for 0.64% of its total share capital [2][3] Group 2 - The buyback activity reflects a trend among companies to return capital to shareholders, with several companies like Country Garden Services (06098) and Baidu-W (02423) also engaging in significant buybacks [1][2] - The buyback amounts and share counts vary significantly across companies, with some like Weigao Group (01066) and Yunda Automotive (03669) showing higher percentages of total share capital repurchased, at 6.68% and 1.27% respectively [2][3] - The data indicates a diverse range of industries participating in buybacks, including technology, healthcare, and consumer services, suggesting a broad interest in enhancing shareholder value across sectors [1][2]

Investment Rating - The industry investment rating is "stronger than the market," indicating an expected performance that exceeds the market by more than 5% within the next six months [25]. Core Insights - The report highlights a divergence in the performance of various segments within the consumer sector, with a stable overall market performance but most sub-sectors underperforming compared to the broader market [4][6]. - There is an expectation for consumer demand to improve ahead of the Lunar New Year, driven by sufficient market liquidity [4]. - The tourism sector is showing potential for growth, with leading companies responding effectively to changing consumer demands [4]. - The beauty industry is experiencing steady growth, with a focus on companies that adapt quickly to market dynamics [4]. - The food and beverage sector is seeing a recovery in supply-demand relationships, particularly in dairy products, while the restaurant supply chain is stabilizing [4]. - In the liquor segment, leading companies are expected to maintain market share despite recent profit adjustments [4]. Market Performance Review - The Shanghai Composite Index fell by 0.57% during the week of January 12-16, with the media sector rising by 3.34% while other sectors like food and beverage and agriculture saw declines of 2.03% and 3.49% respectively [6][8]. Social Services - The report emphasizes the importance of companies that actively respond to changes in consumer demand, particularly in tourism and beauty sectors [4]. Industry Dynamics - The People's Bank of China has introduced measures to enhance structural monetary policy support, which may positively impact consumer spending and economic recovery [10]. - The Philippines has announced visa-free entry for Chinese citizens, which could boost tourism [11]. Company Announcements - Companies like Giant Biological and Proya are making strategic moves, such as product approvals and share buybacks, indicating proactive management in response to market conditions [13][19]. - The report notes significant developments in the liquor industry, including the launch of premium products and partnerships for promotional events [20].

Company Dynamics - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a recombinant collagen and hyaluronic acid composite solution [1] - The approval of this product is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Comments - The approval of the world's first recombinant collagen and hyaluronic acid composite solution for improving cheek smoothness represents the second medical aesthetic license obtained by the company [2] - The company plans to steadily advance the product's market launch and promotion through a diverse product portfolio, comprehensive channel network, and refined brand operations, aiming to strengthen its leading market position in the health and beauty sector [2] Future Prospects - The company has a rich pipeline of aesthetic medicine products, with the cross-linked neck wrinkle product having received national priority review qualification, and the cross-linked nasolabial fold product progressing smoothly [2] - The successful approval of the first two aesthetic products has validated the company's technological leadership and safety, with strong channel resources and operational experience expected to facilitate the rollout of future products [2] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for its cosmetics product matrix and channel expansion, with a rich reserve of new products, including multiple new offerings from the 可复美胶原修护, 焦点, and 秩序 series planned for launch [2] - The company is also upgrading its 可丽金 brand and plans to introduce new products by 2026, while collaborating with key influencers like Li Jiaqi to enhance marketing efforts [2] - The company aims to strengthen its online presence through influencer partnerships and expand its offline coverage in cinema lines, OTC, and CS/KA channels, as well as its own store layout [2] Profit Forecast and Valuation - The company maintains its net profit forecast for 2025-2026 and introduces a net profit estimate of 2.4 billion for 2027, with the current stock price corresponding to a 16x and 14x P/E for 2026-2027 [2] - The company maintains an outperform rating and a target price of 56 HKD, corresponding to a 25x and 23x P/E for 2026-2027, indicating a potential upside of 55% [2]

Group 1 - The core point of the article is that Juzhi Biotechnology has been actively repurchasing its shares, indicating a potential confidence in its stock value and future performance [1] - On January 16, the company repurchased 400,000 shares at a price range of HKD 35.580 to HKD 36.320, totaling HKD 14.4081 million [1] - Since January 5, the company has conducted share repurchases for 10 consecutive days, accumulating a total of 4 million shares repurchased and a total expenditure of HKD 140 million [1] Group 2 - The stock price on January 16 closed at HKD 35.820, reflecting a decrease of 0.61% for the day, with a total trading volume of HKD 404 million [1] - During the repurchase period, the stock has seen a cumulative increase of 4.68% [1] - Detailed repurchase data shows consistent buying of 40,000 shares each day, with varying prices and total amounts spent [2]